The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents | ||||
| African Journal of Gastroenterology and Hepatology | ||||
| Volume 1, Issue 1, December 2018, Page 1-9 PDF (462.13 K) | ||||
| Document Type: Case Reports | ||||
| DOI: https://dx.doi.org/10.52378/kxkq8987 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amr Shaaban Hanafy   ; Waseem M Seleem; Salem Youssef Mohamed
| ||||
| Internal Medicine Department, Hepatogastroenterology Unit – Zagazig University. Egypt | ||||
| Abstract | ||||
| Background and aim Experts have reported thrombocytopenia is linked to chronic liver disease in up to 70% of patients with advanced fibrosis and portal hypertension. The occurrence of thrombotic thrombocytopenic purpura (TTP) with HCV infection is a rare and life-threatening event. We aim to investigate the causes of disturbed conscious levels, acute hemolytic anemia, and severe thrombocytopenia in a patient with chronic HCV and under treatment with direct-acting antivirals. Case report: Development of severe thrombocytopenia, acute hemolytic anemia, neurological symptoms in the form of fits and coma in a 32- year- older man with chronic HCV infection after one week of treatment with direct-acting antivirals (sofosbuvir 400mg PO daily, and daclatasvir 60 mg daily PO). Brain CT was normal, with a negative Coombs test and the presence of schistocytes in the peripheral blood smear. The patient presentation was suggestive of thrombotic thrombocytopenic purpura (TTP). Conclusion: This is a case of TTP after one week of direct-acting antiviral drugs despite the safety profile of these medications. Studying the pathophysiology of TTP after DAAs needs more clarification. | ||||
| Keywords | ||||
| HCV; Thrombocytopenic purpura; direct-acting antivirals | ||||
|
Statistics Article View: 211 PDF Download: 118 |
||||
